Soleus Capital Management L.P. Raises Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Soleus Capital Management L.P. raised its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 5.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,681,242 shares of the biopharmaceutical company's stock after buying an additional 146,702 shares during the period. TG Therapeutics accounts for about 5.1% of Soleus Capital Management L.P.'s portfolio, making the stock its 3rd largest holding. Soleus Capital Management L.P. owned about 1.72% of TG Therapeutics worth $80,705,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TGTX. Barclays PLC increased its stake in shares of TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after purchasing an additional 158,323 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of TG Therapeutics by 52.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 8,112 shares of the biopharmaceutical company's stock valued at $244,000 after buying an additional 2,803 shares in the last quarter. Daymark Wealth Partners LLC raised its position in shares of TG Therapeutics by 1.7% in the fourth quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock valued at $1,249,000 after buying an additional 689 shares in the last quarter. Avaii Wealth Management LLC raised its position in TG Therapeutics by 4.9% during the fourth quarter. Avaii Wealth Management LLC now owns 30,393 shares of the biopharmaceutical company's stock valued at $915,000 after purchasing an additional 1,409 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC acquired a new position in TG Therapeutics during the fourth quarter valued at approximately $228,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Trading Up 1.0%

Shares of TG Therapeutics stock traded up $0.33 during trading on Friday, hitting $34.57. The company's stock had a trading volume of 1,042,767 shares, compared to its average volume of 2,983,166. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a 52 week low of $15.16 and a 52 week high of $46.48. The stock has a market cap of $5.49 billion, a price-to-earnings ratio of -345.67 and a beta of 2.21. The stock has a 50-day moving average price of $38.13 and a two-hundred day moving average price of $34.22.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. During the same period in the prior year, the firm earned ($0.07) EPS. The business's revenue for the quarter was up 90.4% compared to the same quarter last year. Equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Wall Street Zen raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $40.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.